Speaker:
Leif Bergsagel, MD, FASC, Mayo Clinic College of Medicine and Science
Upon completion of this activity, learners should be able to:
* Describe six main genetic subtypes of MM, their prognosis, and the mechanisms of progression
* Explain how small molecules used for the treatment of MM each target plasma cell super-enhancers
* Review novel approaches to targeting enhancer dysregulation in MM
* Discuss how preclinical mouse models of MM can be used to study pathogenesis, targeted and immune therapies
Current Topics in Pathology 2024